XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.

doi:10.7314/apjcp.2013.14.2.701

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2013

Zhang Tian, Sun Jing, Lv Min, Zhang Lin, Wang Xia, Ren Ji-Chen, Wang Bin

Abstract excerpt

Polymorphisms in XPG are considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We aimed to investigate the role of five potential SNPs of XPG gene on the response to platinum-based chemotherapy in advanced Chinese NSCLC patients. A total of 451 patients with newly diagnosed and histopathologically confirmed primary NSCLC were consecutively collected. XPG rs2296147,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Phytogenic

Share to Carboplatin

Share to Deoxycytidine

Share to Endonucleases

Share to Gemcitabine

Share to Vinblastine

Share to Vinorelbine

Source

Open in PubMed

Identifiers

PMID: 23621222
DOI: 10.7314/apjcp.2013.14.2.701

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.PMID 23621222Read ↗

Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.Semantic proximity Read ↗

XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.Semantic proximity Read ↗

The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.Semantic proximity Read ↗

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.Semantic proximity Read ↗

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer.Semantic proximity Read ↗

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.